Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4045 · 1 trial · 1 indication
Incidence and severity of adverse events (AEs) and serious AEs (SAEs)
Incidence and severity of dose-limiting toxicity (DLT) events
| Arm | Type | Description |
|---|---|---|
| Module 1: AZD4045 monotherapy | EXPERIMENTAL | - |
| Module 1: AZD4045 in association with daratumumab and aldesleukin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AZD4045 | BIOLOGICAL | Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) |
| Daratumumab | DRUG | Anti-CD38 monoclonal antibody |
| Aldesleukin | DRUG | Recombinant human IL-2 |
Inclusion Criteria: * Participant must be 18 years or older at the time of signing the informed consent form. * Participants must have documented diagnosis of MM according to the IMWG diagnostic criteria. * Participant must have one or more of the following measurable disease criteria: * Serum M...
Top 20 of 25 competitors
AZD4045 is an investigational monoclonal antibody being developed for the treatment of relapsed or refractory multiple myeloma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AZD4045 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma.
AZD4045 is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of relapsed or refractory multiple myeloma, and it has not yet been approved for commercial use.
AZD4045 is being evaluated in a Phase 1 clinical trial with the identifier NCT07681596. This trial is a modular, multicenter study enrolling approximately 101 participants with relapsed or refractory multiple myeloma. The study is currently recruiting participants in the United States and Australia.
AZD4045 is being studied in a controlled clinical trial, but the trial is not randomized and is not double-blind. The Phase 1 study NCT07681596 is an open-label, controlled trial enrolling participants with relapsed or refractory multiple myeloma.